One in five young people who experience a venous thromboembolism (VTE)1 will require psychotropic medication within five years, reveals research presented at EuroHeartCare 2015 by Anette Arbjerg Højen, a nurse and PhD student in the Aalborg Thrombosis Research Unit at Aalborg University Hospital in Aalborg, Denmark.
14 June 2015 11:25 CEST (Paris)14 June 2015 10:25 BST (London)14 June 2015 05:25 EDT (New York)
Dubrovnik, Croatia – 14 June 2015: One in five young people who experience a venous thromboembolism (VTE)1 will require psychotropic medication within five years, reveals research presented at EuroHeartCare 2015 by Anette Arbjerg Højen, a nurse and PhD student in the Aalborg Thrombosis Research Unit at Aalborg University Hospital in Aalborg, Denmark. Young VTE patients were twice as likely to experience mental health problems requiring psychotropic medication as their healthy peers.EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions (CCNAP) of the European Society of Cardiology (ESC). The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses.Ms Arbjerg Højen said: “Young VTE patients are scared of having another VTE and of dying. We treat these patients in our Thrombosis Research Unit and have seen how anxious and mentally unwell they can be, even a long time after the VTE occurs. They are troubled and have a hard time accepting the diagnosis since it is generally perceived as an old person’s disease. Young patients can feel different and isolated.”Ms Arbjerg Højen continued: “We know that other chronic medical illnesses in youth can lead to emotional and behavioural problems. However, until now VTE has been considered an acute condition that occurs in older people. There is no follow up of these young patients regarding their mental health and no studies have been done on this issue. But a venous thromboembolism has the characteristics of a chronic illness with a high risk of recurrence (10 year risk of 30%) and the potential for long-term somatic consequences including post thrombotic syndrome characterised by persistent or bursting pain, swelling, or cramping in the limb, pulmonary hypertension, and the need for lifelong medicinal treatment.”This study is the first to investigate the mental health prognosis of young VTE patients. Data from four nationwide registries was used: the Danish Civil Registration System, the Danish National Patient Register, the Danish National Prescription Registry, and the Danish Medical Birth Registry. The researchers identified 4 132 patients aged 13 to 33 who had a first VTE between 1997 and 2010. A control group of 19 292 people without VTE was randomly selected and matched to the patients by sex and birth year.All participants in the study were followed in the prescription registry for their first purchase of psychotropic drugs. These medications alter chemical levels in the brain which impact mood and behaviour and include antidepressants, anti-anxiety medications, sedatives and antipsychotics. Purchase of psychotropic drugs was used as a proxy measure for mental health status and compared between the two groups. Regression analysis was used to exclude other causes of psychotropic drug purchase such as postpartum depression.The researchers found that psychotropic drug purchase was substantially higher among the young VTE patients compared to the control group. Among VTE patients the risk of purchasing psychotropic drugs following their diagnosis was 7.1% after 1 year and 22.1% after 5 years. Their excess risk relative to the controls was 4.7% after 1 year and 10.8% after 5 years.Ms Arbjerg Højen said: “We found that after 5 years, VTE patients have a 10.8% higher risk of using psychotropic drugs than people of the same age without VTE. This was true both for patients with blood clots in the veins in the legs and for those with clots in the veins of the lungs. It means that one in five VTE patients will experience mental health problems requiring psychotropic medication within the first 5 years after diagnosis. That is more than double that of their peers.”She added: “Most of the drugs prescribed were antidepressants. These young patients struggle a lot with the fear of VTE recurrence. They are scared that if it strikes again it could become a pulmonary embolism and they might die. Our study only included patients who received a prescription for psychotropic drugs. There will be others who were not prescribed medication because of their young age so the group with mental health problems could be much larger than what we found.”Ms Arbjerg Højen continued: “Our study looked at mental health up to 5 years and not just in the immediate period after the VTE event, suggesting that it is not just a short term panic. We don’t know how long mental health problems in VTE patients last, but we do know that these patients will always be at high risk of recurrent VTE so there is a possibility that their depression or anxiety could be lifelong if untreated.”She concluded: “Most young VTE patients are monitored by their general practitioner for 3 to 6 months because they are on oral anticoagulant treatment but after that there is generally no long-term follow up. Our study points to the need for treating VTE as a chronic condition with serious mental health consequences requiring specialist care.”ENDS
1 Venous thromboembolism (VTE) is a blood clot in a vein and can be fatal. It includes deep vein thrombosis, which usually occurs in a deep leg vein, and pulmonary embolism, a blockage which can prevent blood from reaching the lungs. Risk factors for VTE include family history, cancer, recent surgery, trauma and autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. VTE is not the same as a blood clot in an artery (called arterial thrombosis), which can lead to heart attack and stroke
About EuroHeartCareEuro Heart Care is the annual congress of the Council on Cardiovascular Nursing and Allied Professions (CCNAP) of the European Society of Cardiology (ESC). This year’s meeting is held in collaboration with the Croatian Association of Cardiology Nurses.About the Council on Cardiovascular Nursing and Allied Professions (CCNAP) The CCNAP aims to promote excellence in Cardiovascular Nursing and Allied Professions through practice education and research. In addition to nurses, allied health professionals belonging to the CCNAP include physiotherapists, dieticians, psychologists, cath lab technicians, imaging and diagnostic technicians and therapists working in rehabilitation and prevention. The CCNAP is one of five Councils of the European Society of Cardiology.About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.Information for journalists attending EuroHeartCare 2015EuroHeartCare 2015 will be held 14-15 June in Dubrovnik, Croatia, at the Valamar Lacroma Dubrovnik Hotel. The full scientific programme is available here • Press registration is conducted via My ESC (Individual Registration / Press):• Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form. (to be sent to email@example.com)• Credential: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event). The ESC media and embargo policy is here: http://www.escardio.org/The-ESC/Press-Office/Press-services/ESC-Media-and-Embargo-Policy• The ESC Press Office will check your credential and confirm your press accreditation by email.• Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives• The decision of the ESC Press Office is final regarding all press registration requests.• The ESC Press Office will verify the documents and confirm by email that your Press Accreditation is valid.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved